We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+1.67%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$929M
AUM Growth
-$261M
Cap. Flow
-$241M
Cap. Flow %
-25.92%
Top 10 Hldgs %
77.4%
Holding
34
New
2
Increased
4
Reduced
22
Closed
3

Top Buys

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$23.1M
2
URGN icon
UroGen Pharma
URGN
+$6.06M
3
NRIX icon
Nurix Therapeutics
NRIX
+$4.04M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$3.66M
5
CTMX icon
CytomX Therapeutics
CTMX
+$3.47M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$165M
2
IMCR icon
Immunocore
IMCR
+$22.3M
3
LEGN icon
Legend Biotech
LEGN
+$20.7M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.77M
5
LQDA icon
Liquidia Corp
LQDA
+$6.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
1
Celldex Therapeutics
CLDX
$2.77B
$124M 13.37%
6,100,729
-399,271
-6% -$7.77M
PCVX icon
2
Vaxcyte
PCVX
$7.89B
$99.9M 10.75%
3,071,588
-128,412
-4% -$4.21M
VERA icon
3
Vera Therapeutics
VERA
$2.54B
$80.7M 8.69%
3,426,887
+1,026,887
+43% +$23.1M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.84B
$79.8M 8.59%
8,520,000
– –
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.37B
$75.8M 8.16%
8,463,742
-464,781
-5% -$4.33M
CGON icon
6
CG Oncology
CGON
$6.11B
$63.9M 6.88%
2,457,667
-153,995
-6% -$3.71M
VRDN icon
7
Viridian Therapeutics
VRDN
$2.13B
$61.9M 6.66%
4,427,927
-272,073
-6% -$3.69M
COGT icon
8
Cogent Biosciences
COGT
$6.79B
$61M 6.56%
8,492,557
-612,443
-7% -$3.4M
BEAM icon
9
Beam Therapeutics
BEAM
$2.58B
$41.1M 4.43%
2,417,647
-100,523
-4% -$1.75M
IMCR icon
10
Immunocore
IMCR
$1.78B
$30.6M 3.3%
976,267
-719,309
-42% -$22.3M
WVE icon
11
Wave Life Sciences
WVE
$1.12B
$29.6M 3.19%
4,560,053
-339,444
-7% -$2.24M
TVTX icon
12
Travere Therapeutics
TVTX
$5.33B
$22.8M 2.46%
1,540,691
-262,059
-15% -$4.34M
TYRA icon
13
Tyra Biosciences
TYRA
$1.82B
$22.3M 2.4%
2,329,998
-76,069
-3% -$723K
DVAX
14
DELISTED
Dynavax Technologies
DVAX
$21.3M 2.29%
2,145,319
-475,478
-18% -$5.01M
ENGN icon
15
enGene Therapeutics
ENGN
$122M
$18.2M 1.96%
4,994,090
– –
CGEM icon
16
Cullinan Oncology
CGEM
$1.05B
$15.8M 1.7%
2,095,998
-242,631
-10% -$1.95M
NRIX icon
17
Nurix Therapeutics
NRIX
$2.43B
$13.4M 1.44%
1,173,605
+373,605
+47% +$4.04M
RLAY icon
18
Relay Therapeutics
RLAY
$4.02B
$9.99M 1.08%
2,887,014
-176,278
-6% -$524K
AMRN
19
Amarin Corp
AMRN
$284M
$9.34M 1.01%
576,111
-44,620
-7% -$502K
URGN icon
20
UroGen Pharma
URGN
$2B
$9M 0.97%
656,573
+631,573
+2,526% +$6.06M
CTMX icon
21
CytomX Therapeutics
CTMX
$705M
$4.89M 0.53%
+2,154,413
New +$3.47M
GERN icon
22
Geron
GERN
$911M
$4.87M 0.52%
3,456,318
-203,208
-6% -$288K
IRWD icon
23
Ironwood Pharmaceuticals
IRWD
$611M
$3.92M 0.42%
5,466,825
-356,113
-6% -$280K
CRBU icon
24
Caribou Biosciences
CRBU
$156M
$3.87M 0.42%
3,067,774
-201,373
-6% -$198K
STRO icon
25
Sutro Biopharma
STRO
$379M
$3.63M 0.39%
508,810
-35,335
-6% -$289K
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Kynam Capital Management held 34 positions worth $929M, down 22% from $1.19B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Kynam Capital Management withdrew a net $241M in Q2 2025, closing 3 positions and reducing 22 holdings. Its most notable exit was Natera, an estimated $165M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Edgewise Therapeutics worth $3.33M.

  • Kynam Capital Management's largest Q2 2025 buy was Edgewise Therapeutics: 253,979 shares worth $3.33M.
  • Kynam Capital Management added most to Vera Therapeutics in Q2 2025, an estimated $23.1M increase.
  • Kynam Capital Management's biggest Q2 2025 reduction was Immunocore, cutting an estimated $22.3M.
  • Kynam Capital Management fully exited Natera in Q2 2025, selling an estimated $165M.
  • Kynam Capital Management's ten largest holdings make up 77% of its $929M portfolio in Q2 2025.
  • Kynam Capital Management opened 2 new positions and closed 3 in Q2 2025.
  • Kynam Capital Management's portfolio value fell 22% quarter-over-quarter to $929M.

Based on Kynam Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.